Download presentation
Presentation is loading. Please wait.
1
Fibroblast Growth Factor 23 NEW INSIGHTS INTO CHRONIC KIDNEY DISEASE
ESPN Lyon 2008 J Bacchetta, Lyon
2
Outline FGF23, the new hormone of the bone/kidney axis
FGF23, biochemical and structural properties FGF23, physiological roles: regulation of phosphate and 1-25 OH vitamin D FGF23 deficiency and related diseases FGF23 excess and related diseases FGF23 and chronic kidney disease Conclusion & perspectives
3
FGF23, the new hormone of the bone/kidney axis
A phosphatonin described in the early 2000’s FGF23 mutation in ADHR (Nat Genet. 2000) Tumor-induced osteomalacia (Shimada, PNAS 2001) FROM BEDSIDE TO BENCH A protein synthesized by bone Osteocytes, osteoblasts and odontoblasts A complex of 3 elements for biological activity FGF23 FGF-R: tyrosine kinase receptor Klotho: cofactor Anti-aging protein Tissue-specific expression (kidney and parathyroid gland)
4
FGF23, biochemical and structural properties
Chromosome 12p13 Protein amino-acids, 30 kDa FGF19 subfamily, the ‘endocrine’ FGFs Systemic action Stabilization of the β-trefoil structure by a disulfide bond Two forms: active/inactive 1 25 180 251 FGF homology region Specific region CLEAVAGE ACTIVE FGF23 INACTIVE FGF23 RXXR + 25 180 251 25 251
5
FGF23, different assays Two different types of assays (ELISA)
Intact FGF23: active form Antibody against C-term fragment: total FGF23, active and inactive forms Limited data in children 1 study (total FGF23), 26 children (Jonsson, NEJM 2003) Renal function: not defined λ λ λ 251 25 180 251 25 + У У У ACTIVE FGF23 INACTIVE FGF23
6
FGF23, physiology and regulation
FGF23 regulation not yet clear Potential regulatory mechanisms Direct effect on FGF23 promoter (VDR in osteoblasts) KIDNEY No direct effect on FGF23 promoter 1,25 OH D3 PHEX P, Ca, PTH (+) (-) (+) (-) FGF 23 MEPE (-) (-) BONE DMP1 (+) Bone mineralization
7
Bone cell FGF23 Parathyroid cell Klotho Distal tubule Bone cell ?
Active FGF23 FP convertase PTH,1-25 OH D3 (+) Bone cell FGF23 Inactive FGF23 Parathyroid cell FGF-R Inhibition of PTH secretion and gene expression Klotho Distal tubule (+) Calcium reabsorption (+) Erk Phosphorylation (-) Bone cell Inhibition of osteoblastic differenciation and mineralization (+) TRPV5 (-) Phosphaturia (-) Npt2a/2c (-) ? Decreased 1α OHase Increased 24 OHase Choroid plexus Decreased 1,25 OH D3 Proximal tubule
8
Animal models of FGF23 deficiency
WT FGF23 -/- Animal models of FGF23 deficiency Memon 2008 FGF 23 -/- Klotho -/- Life span Shortened; accelerated aging Reproductive function Infertility Bone Osteopenia Calcifications Soft tissue and medial vascular calcification Clinical features Skin atrophy, neuronal degeneration, pulmonary emphysema, hypoglycemia Biology Increased tubular phosphate reabsorption Hyperphosphatemia Increased expression of Npt2a in kidney Increased 1,25 OH vitamin D3 serum level Hypercalcemia Clinical symptoms probably arise from excess of phosphate rather than vitamin D Low phosphate diet: rescues phenotype and prevents vascular calcifications Low vitamin D diet: improves survival but does not prevent vascular calcifications Transfer of 1αOHase deficiency: rescues phenotype
9
FGF23 deficiency and related diseases
Topaz 2006 Ichikawa, JCI 2007 FGF23 deficiency and related diseases Familial tumoral calcinosis Peri-articular, visceral and vascular calcifications Hyperostosis, specific dental abnormalities Biology: hyperphosphatemia, hypoparathyroidism Genetics: recessive and dominant autosomal inheritance FGF23 inactivating mutation GALNT3 mutation (impaired glycosylation of FGF23) KLOTHO mutation : high FGF23 concentration
10
FGF23 excess and related diseases
Tumor-induced osteomalacia McCune-Albright Sd and fibrous dysplasia of bone Epidermal nevus syndrome Hypophosphatemic rickets X-linked HR PHEX mutation (Xp22) Autosomal dominant HR FGF23 mutation Autosomal recessive HR DMP1 inactivating mutation Other types HR + hypercalciuria Npt2c: autosomal recessive ClCN5: X-linked HR, hyperPTH and dysmorphy: Klotho activating translocation
11
FGF23 and CKD
12
Mineral and Bone Disorders in CKD children
Ca-P Hypocalcemia Hyperphosphatemia Hormones Hyperparathyroidism Decreased vitamin D Bone Delayed bone maturation Decreased bone mass Pain, deformations Increased fracture risk Growth Resistance to GH Muscles Proximal myopathy Vessels Calcifications Eye Corneal calcifications Band keratopathy Skin Soft tissue necrosis Pruritus GFR < 90 mL/min per 1.73 m2 Long term Bone damage Drug toxicity Inflammation Anemia Metabolic acidosis Resistance to GH Vascular calcifications Morbidity and mortality
13
FGF23 and CKD Reduced nephron number Decreased urine phosphate
excretion Decreased FGF23 clearance? Decreased number of CaR and VDR Decreased 1-25 OH vitamin D Hypocalcemia Hyperphosphatemia Vitamin D analog Hyperparathyroidism Increased FGF23 level Urine phosphate excretion (limitation due to reduced nephron number) Stimulatory and inhibitory effect
14
FGF23 and CKD Increased FGF23 FGF23: active in CKD?
Early stages of CKD, prior to hyperphosphatemia Both intact and C-term FGF23 FGF23: active in CKD? Accumulation in dialysis patients Relative Klotho deficiency? Sites with co-expression of Klotho and FGF-R Cognitive function? Growth?
15
FGF23 and CKD in adult patients
FGF23: a novel independent risk factor of progression of CKD in 177 non diabetic adult patients Prospective follow-up 53 months Fliser et al., JASN 2007 GFR C-term FGF23 Phosphate PTH
16
FGF23, CKD and therapeutic response
At short term (Imanishi, KI 2005) Intact FGF23 predictor of refractoriness to iv calcitriol therapy In association with high serum PTH level (PPV 88 % and NPV 4 %) 24 weeks 62 HD patients At long term (Kazama, KI 2005) Baseline intact FGF23 predictor of refractory hyperparathyroidism 2 years 103 non diabetic HD patients Nakanishi, KI 2005
17
FGF23 and CKD children 141 children, 10.8±4 years ( ), GFRinulin 100±34 mL/min per 1.73 m² (27-234) KDOQI I KDOQI II KDOQI III Hyperfiltration N 71 33 16 20 GFR * 110 ± 11 76 ± 9 46 ± 8 151 ± 27 FGF23 * 63 ± 89 96 ± 235 103 ± 62 66 ± 52 PTH * 32 ± 11 49 ± 19 69 ± 22 34 ± 17 25OH 23 ± 9 23 ± 8 21 ± 7 21 ± 11 120 children, KDOQI 1,2,3 r= ; P < 0.001 J Bacchetta, et al. Unpublished results
18
FGF23, CKD and vascular calcifications
Association between reduced BMD and vascular calcifications FGF23: not a biomarker of coronary calcifications in subjects with normal kidney function Roos et al., Clin Endocrinol 2008 64 subjects with normal kidney function No correlation between intact FGF23 and coronary artery score FGF23: biomarker of medial peripheral artery calcification in CKD patients? Inaba, Osteoporos Int. 2006 Inversely correlated to hand arteries, not to aortic calcifications FGF23 and vascular calcifications: unclear pathophysiology Direct inhibition of calcification? Indirect inhibition of vascular calcification By inhibiting hydroxylation of vitamin D? By lowering phosphate levels?
19
‘Take-home message’ FGF23/Klotho
New insight to the understanding of Ca-P metabolism Two hormones - a strong interplay Two key roles: phosphaturia and inhibition of 1a-OHase FGF23 and CKD Toxic? Beneficial? Monitoring? FGF23 and cardiovascular protection? Future: rh-FGF23? FGF23 Ab? Ca P PTH Vit D FGF23
20
Acknowledgements Centre de Référence des Maladies Rénales Rares, Hôpital Femme Mère Enfant, Lyon P Cochat, B Ranchin, A Liutkus P Abou-Jaoude, A Pinçon, M Afanetti Service d’Exploration Fonctionnelle Rénale et Métabolique, Hôpital Edouard Herriot, Lyon L Dubourg Département de Biologie Ostéoarticulaire, Hôpital Edouard Herriot, Lyon M Richard S Arnaud INSERM U831, Lyon PD Delmas I Rondy
Similar presentations
![Ca ++ and P i Homeostasis. Ca ++ in the plasma [Ca ++ ] in plasma: 2.5 mM, of which about ½ is bound and thus physiologically inactive. Ratio of free/bound.](/12/3581741/big_thumb.jpg "Ca ++ and P i Homeostasis. Ca ++ in the plasma [Ca ++ ] in plasma: 2.5 mM, of which about ½ is bound and thus physiologically inactive. Ratio of free/bound.>")
